Denny Won

Cooley advised the underwriters on the $250.1 million initial public offering of Neumora Therapeutics, a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed.

Cooley advised the underwriters in Merus’ $172.5 million follow-on offering. Jefferies, BofA Securities, Guggenheim Securities and William Blair acted as joint book-running managers for the offering. Merus is a clinical-stage oncology company developing innovative, full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics. Partners Denny Won, Courtney Thorne and Div Gupta led the Cooley team.

Cooley advised the underwriters in the upsized initial public offering of Sagimet Biosciences, a clinical-stage biotechnology company, at $85 million.

Cooley advised the underwriters in IGM Biosciences’ $97.5 million public offering of 9,000,000 shares of non-voting common stock and 3,187,500 shares of voting common stock, each at the public offering price of $8.00 per share, as well as a $22.5 million concurrent private placement. IGM is a clinical-stage biotechnology company committed to developing and delivering a new class of medicines to treat patients with cancer, autoimmune and inflammatory diseases, and infectious diseases. Denny Won, Kristin VanderPas and Charlie Kim led the Cooley team.

Cooley advised the underwriters in Erasca’s $100 million follow-on offering of 15,384,616 shares of common stock at a public offering price of $6.50 per share. Erasca is a clinical-stage biopharmaceutical company discovering, developing and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Partners Charlie Kim, Kristin VanderPas and Denny Won led the Cooley team.